Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) Cost of Revenue (2018 - 2025)

AVITA Medical (RCEL) has disclosed Cost of Revenue for 7 consecutive years, with -$5.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 84.1% year-over-year to -$5.6 million, compared with a TTM value of $12.8 million through Dec 2025, up 40.69%, and an annual FY2025 reading of $12.8 million, up 40.69% over the prior year.
  • Cost of Revenue was -$5.6 million for Q4 2025 at AVITA Medical, down from $12.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $31.3 million in Q4 2023 and bottomed at -$35.0 million in Q4 2024.
  • Average Cost of Revenue over 4 years is $3.6 million, with a median of $2.5 million recorded in 2023.
  • Peak annual rise in Cost of Revenue hit 658.25% in 2024, while the deepest fall reached 211.77% in 2024.
  • Year by year, Cost of Revenue stood at -$9.5 million in 2022, then soared by 428.51% to $31.3 million in 2023, then plummeted by 211.77% to -$35.0 million in 2024, then surged by 84.1% to -$5.6 million in 2025.
  • Business Quant data shows Cost of Revenue for RCEL at -$5.6 million in Q4 2025, $12.1 million in Q3 2025, and $3.5 million in Q2 2025.